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ABSTRACT 
Major depressive disorder is a heritable neuropsychiatric syndrome characterized by relatively subtle cellular and molecular alterations localized to a complex network of neural 
substrates. Various forms of psychotherapy, pharmacotherapy, and electroconvulsive therapy (ECT) are currently the most commonly used antidepressant treatments. Despite 
adequate care with currently available treatments, up to 70% of depressed patients have residual symptoms, and, even with more aggressive therapies, 20% or more may show 
only a limited response. The need for newer compounds to treat depression is still an ever growing concern due to the enormous societal and famifications of depression. This 
review covers all the monoaminergic (SSRI/5-HT1A antagonists, SSRI/5-HT2C antagonists, SSRI/alpha-2 adrenergic antagonists, triple reuptake inhibitors, dopamine agonists, 
targeting GABA) and beyond monoaminergic strategies including corticotropin-releasing factor (CRF)-1 receptor antagonists, Inhibition of glucocorticoid function, substance P 
(Nk-1)  antagonists,  MCH1  receptor  antagonists,  Gal3  receptor  antagonists,  arginine  vasopressin  as  the  potential  novel  targets  for  depression..  However,  To  be  the  most 
successful novel target it shouldn’t  only demonstrate preclinical antidepressant like effects, but also target the unmet clinical needs and lead to long-term disease modification.  
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INTRODUCTION 
Depression is one of the top ten causes of morbidity and mortality, 
afflicting up to 20% of the world's population
1,2. In addition to its 
social  toll,  the  economic  burden  of  depression  contributes 
approximately $44 billion in lost productivity annually in the United 
States
3. The symptoms of depression are chronic, recurring, and life 
threatening
2.  Despite  adequate  care  with  currently  available 
treatments, up to 70% of depressed patients have residual symptoms, 
and, even with more aggressive therapies, 20% or more may show 
only a limited response
4,5. Rather than being the exception, recurrent 
episodes are the rule, and there are few evidence-based approaches 
to  help  clinicians  maintain  a  patient’s  antidepressant  response. 
Persistent depression is associated with an increase in substance and 
alcohol abuse, an increased risk for suicide and for cardiovascular 
disease.  Thus,  improved  treatments  for  depression  are  urgently 
needed
6. 
Current Antidepressant Treatments 
Despite  the  relative  lack  of  knowledge  of  the  aetiology  and 
pathophysiology of depression, there are good treatments for it, with 
most  patients  showing  significant  improvement  with  optimal 
treatment.  Mild  depression  responds  to  different  forms  of 
psychotherapy. Mild and more severe forms of depression respond 
to  a  host  of  antidepressant  medications,  with  a  combination  of 
medication  and  psychotherapy  providing  optimal  treatment. 
Electroconvulsive therapy (shock treatment) is one of most effective 
treatments  for  depression,  but  is  usually  reserved  for  the  more 
severely ill due to the availability of numerous pharmacotherapies. 
The  utility  of  other  so-called  somatic  therapies  is  under 
investigation. Almost all of the available medications for depression 
are based on chance discoveries that were made more than half a 
century ago. Most of today’s medications are based on the tricyclic 
antidepressants, which are believed to act by inhibiting the plasma 
membrane transporters for serotonin and/or noradrenaline
7,8. Current 
pharmacological  antidepressant  treatments  improve  depressive 
symptoms  through  complex  mechanisms  that  are  themselves 
incompletely understood
9. The need for newer compounds to treat 
depression is an ever growing concern due to the enormous societal 
and famifications of depression
10. These older medications provided 
a template for the development of newer classes of antidepressant, 
including the SSRIs (selective serotonin reuptake inhibitors), NRIs 
(noradrenaline  reuptake  inhibitors)  and  SNRIs  (serotonin  and 
noradrenaline  reuptake  inhibitors).  However,  as  these  newer 
medications  have  the  same  mechanism  of  action  as  the  older 
tricyclics,  their intrinsic  efficacy  and range  of  patients  for  whom 
treatment  is  successful  remain  the  same.  The  older  monoamine 
oxidase  inhibitors,  which  reduce  the  enzymatic  breakdown  of 
serotonin  and  noradrenaline,  are  also  still  used  today  with  great 
success.  Although today’s  treatments  for  depression are  generally 
safe and effective, they are far from ideal. Therefore there is still a 
great need for faster acting, safer and more effective treatments for 
depression
11. 
The Search For Novel Antidepressants 
Various  forms  of  psychotherapy,  pharmacotherapy,  and 
electroconvulsive therapy (ECT) are currently the most commonly 
used  antidepressant treatments.  Serendipitous  discoveries  and/or a 
limited  understanding  of  the  neurobiology  of  depression  which 
largely focused on the monoaminergic neurotransmitter systems led 
to the development of many of these treatments. As knowledge of 
the neuroscience of depression advances, a number of novel targets 
for  antidepressant  treatment  are  being  uncovered  and  actively 
investigated.  Generally,  these  treatments  fall  into  three  major 
categories:  first,  medications  that  optimize  the  modulation  of 
monoaminergic  neurotransmitters;  second,  medications  that  target 
monoamine  neurotransmitter  and  neuromodulatory  systems;  and 
third, devices that produce focal electrical brain stimulation targeting 
brain regions implicated in the pathophysiology of depression
6. In 
this review, we discuss these treatments and highlight those that hold 
the most promise.
 
Monoaminergic Strategies 
The  monoamine  hypothesis  of  depression  postulates  that  the 
etiology  and  pathogenesis  of  depression  arises  from  central 
deficiencies  in  serotonin,  norepinephrine,  and/or  dopamine. 
Correspondingly, current pharmacotherapies have been developed in 
an effort to amend these alterations in monoaminergic systems (e.g., 
SSRIs, SNRIs). Regardless of their mechanism of action, however, a 
drawback of all marketed antidepressants is the 3- to 5-week delay 
necessary to achieve therapeutic efficacy. This lag time is thought to 
reflect  the  time  required  for  desensitization  of  the  receptors 
regulating  monoamine release  (e.g.,  5-HT1A,  5-HT2C,  and  5-HT1A 
and α2 adrenergic receptors). To potentially accelerate the onset of Mehta Hiren R et al. IRJP 2011, 2 (12), 132-138 
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antidepressant action as well as limit unwanted side effects  current 
drug  development  strategies  are  focusing  on  designing  new 
antidepressants  with  dual  and/or  triple  modes  of  action.  These 
approaches, along with examples of preclinical and clinical studies, 
will be highlighted in the following sections.  
SSRI/5-HT1A antagonists 
The  delayed  clinical  efficacy  of  SSRIs  is  believed  to  result,  to a 
large extent, from the indirect activation of somatodendritic 5-HT1A 
autoreceptors.  A  profound  body  of  preclinical  literature  indicates 
that acute SSRI treatment increases serotonin levels in various brain 
regions including the dorsal raphe nuclei. This elevation in serotonin 
engages inhibitory 5-HT1A autoreceptors residing in the dorsal raphe 
to inhibit 5-HT cell firing and dampen subsequent 5-HT release in 
terminal serotonergic brain regions
12. However, following long-term 
SSRI treatment (14–21 d) 5-HT1A autoreceptors desensitize resulting 
in more pronounced elevations in serotonin levels compared to acute 
treatment
13,14. These data suggest that a strategy combining SSRIs 
with 5-HT1A receptor antagonists would produce robust and more 
rapid  increases  in  central  serotonin  levels  and  likely  yield  an 
antidepressant  with  an  accelerated  onset  of  activity.  This 
neurochemical  hypothesis  is  supported  by  a  plethora  of 
microdialysis studies demonstrating that pretreatment with selective 
5-HT1A  antagonists  such  as  WAY-100635  augments  SSRI-  and 
SNRI-induced changes in cortical serotonin levels
15.
 
Preclinical  models  sensitive  to  the  behavioral  effects  of 
serotonergics  corroborate  these  findings  as  5-HT1A  antagonism  is 
reported to potentiate the antidepressant-like effects of SSRIs in the 
rodent  resident-intruder,  social  interaction,  and  schedule-induced 
polydipsia assays
16-18. Clinical data using this combination strategy 
demonstrate that the antidepressant activity of SSRIs is accelerated 
and/or  enhanced  when  combined  with  the  mixed  5-HT1A/alpha 
adrenoceptor antagonist, pindolol
19. As some  of these dual acting 
SSRI/5-HT1A compounds begin their clinical evaluation, it may only 
be a matter of time to determine whether this approach will represent 
the newest generation of antidepressants. 
SSRI/5-HT2C antagonists 
Desensitization of 5-HT2C receptors is routinely reported following 
chronic SSRI treatment. However, the overall contribution of this 
molecular change to the antidepressant effects of SSRIs is not well 
understood. Recent data suggest that 5-HT2C receptor inactivation 
may play a role in augmenting the neurochemical and behavioral 
effects of antidepressants. Using in vivo microdialysis techniques in 
rats,  Cremers  et  al.  and  others  showed  that  the  selective  5-HT2C 
antagonists, SB 242084 and RS102221, and the nonselective 5-HT2C 
receptor  antagonists,  ketanserin  and  irindalone,  potentiate  the 
neurochemical  effects  of  SSRIs  on  hippocampal  and  cortical 
serotonin levels
20,21. Despite the robust neurochemical effects when 
these agents are combined, 5-HT2C receptor antagonism alone has no 
significant  effects  on  extracellular  serotonin
21,22.  Similar  to  the 
reported  neurochemical  effects,  this  serotonergic  combination 
produces marked augmentation of the antidepressant-like effects of 
SSRIs in behavioral models of depression and anxiety including the 
mouse tail suspension test (TST) and schedule-induced polydipsia 
assay
20,22.  Complementary  studies  done  in  5-HT2C  receptor  null 
mutant mice show enhanced neurochemical and behavioral (TST) 
responses  to  fluoxetine  compared  to  their  wild-type  littermates
22. 
Overall,  these  preclinical  data  show  that  5-HT2C  antagonism 
augments  the  neurochemical  and  behavioral  effects  of  SSRIs. 
Moreover, these data highlight a novel strategy of combining both 
targets, either in a single molecular entity or as adjunctive therapy to 
already marketed SSRIs,  for the potential treatment of depressive 
disorders.
 
SSRI/alpha-2 adrenergic antagonists 
The success of SNRIs in the clinic underscores the importance of 
elevating  both  norepinephrine  and  serotonin  in  the  treatment  of 
depression.  However,  a  strategy  that  targets  noradrenergic 
autoreceptors  may  have  merit  in  augmenting  the  neurochemical 
effects  of  conventional  antidepressants.  Several  classes  of 
antidepressants, particularly norepinephrine reuptake inhibitors such 
as reboxetine (Edronax) and the SNRIs, acutely elevate extracellular 
levels of norepinephrine. The release of norepinephrine can activate 
presynaptic  alpha-2  adrenergic  autoreceptors  located  on  both 
norepinephrine  and  dopamine  cells  causing  blunted noradrenergic 
and  dopaminergic  responses,  respectively.  Thus,  antidepressants, 
when  given  in  combination  with  agents  that  “turn  off  ”  alpha-2 
autoreceptors,  can  potentially  elevate  levels  of  all  three 
monoamines.  Neurochemical  validation  of  this  hypothesis  comes 
from  microdialysis  studies  showing  that  alpha-2  adrenergic 
antagonists  markedly  potentiate  the  ability  of  antidepressants  to 
increase  extracellular  levels  of  norepinephrine,  serotonin,  and 
dopamine,  depending  on  the  brain  region  examined
23.  Although 
there are essentially no published data showing that this particular 
combination strategy is efficacious in preclinical behavioral models 
of depression, the data from microdialysis studies suggest that alpha-
2 adrenergic antagonism may strengthen the neurochemical effects 
of antidepressants, and may improve the efficacy of antidepressants 
in humans
24. In addition, nonselective alpha-2 adrenergic receptors 
antagonists such as mirtazapine (Remeron) are reported to possess 
modest antidepressant activity in their own right
25. Finally, clinical 
studies emphasize that combining SSRIs with nonselective alpha-2 
receptor antagonists actually shortens the time required to achieve 
antidepressant activity
26,27. 
Collectively, these data have ignited considerable chemistry efforts 
to  design  and  synthesize  novel  antidepressant  molecules  that 
combine  monoamine  reuptake  inhibition  with  alpha-2  adrenergic 
receptor antagonism
28,29.
 
Triple Reuptake Inhibitors 
Triple reuptake inhibitors block synaptic reuptake of 5- HT, NE, and 
DA.  Animal  studies have  demonstrated  antidepressant-like  effects 
for several of these compounds
30-35. DOV 216 303, one such agent, 
was found to be safe and tolerable during short-term use in a Phase 
1, open-label study
35. Tesofensine (NS 2330), another compound, 
has  shown  modest  preliminary  safety  and  efficacy  in  treating  the 
motor symptoms of Parkinson’s Disease (PD)
36, but clinical data in 
treating depression are unavailable. The success, however, of these 
compounds as well as the strategy and benefit of combing inhibition 
of  all  three  monoamines  into  a  single  molecule    is  still awaiting 
evaluation in human patients. 
Additional Multitarget, Monoamine Strategies 
Both  transporter  and  inhibitory  autoreceptor  mechanisms  strictly 
control  the  release  of  biogenic  amines  into  the  extracellular 
environment.  For  instance,  5  HT1A  and  5-HT1B  receptors  are 
somatodendritic and terminal autoreceptors, respectively, regulating 
levels  of  central  serotonin  levels.  Blockade  of  5-HT1B  receptors 
alone has been shown to acutely increase levels of serotonin in the 
guinea pig frontal cortex and hippocampus as well as augment the 
effects of SSRIs on serotonin levels
37. Combining the selective 5-
HT1A  antagonist,  WAY-100635,  with  the  5-HT1B  receptor 
antagonist,  SB-224289,  produced  marked  elevations  in  serotonin 
levels  in  the  guinea  pig
38.  These  results  curiously  suggest  that 
combining  5-HT1A  and  5-HT1B  receptor  antagonism  can  elevate 
serotonin and, consequently, potentially be an effective strategy to 
treat  depression.  Additional  examples  of  targeting  multiple 
postsynaptic receptors as putative antidepressant agents include the 
5-HT1A  agonist/alpha-2  antagonist,  sunepitron,  the  5-HT1A 
agonist/dopamine  D2  agonist,  roxindole,  and  alpha-2  adrenergic 
antagonist/5-HT2  antagonist,  mirtazapine
39.  In  summary,  these 
strategies seem to efficiently “tweak” the monoaminergic systems in 
the  hopes  of  developing  a  more  rapid  acting  antidepressant. 
However, much needed clinical data regarding the efficacy, safety, Mehta Hiren R et al. IRJP 2011, 2 (12), 132-138 
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and tolerability of such “dual-acting” compounds is eagerly awaited. 
Perhaps  newer  approaches  targeting  convergent,  downstream 
components of the monoamine system (e.g., neurotrophins) and/or 
nonmonoaminergic  systems  including  GABA  and  glutamate  may 
ultimately  prove  beneficial  in  the  clinical  management  of 
depression. 
Dopamine agonists 
Dopamine  D2/D3  receptor  agonists  include  pramipexole  and 
ropinirole.  Two  placebo-controlled  trials  have  confirmed  that 
pramipexole  is  efficacious,  safe,  and  tolerable  in  patients  with 
bipolar  depression
40,41.  Pramipexole  may  also  be  effective  in 
treatment-resistant unipolar depression as demonstrated in an open-
label  study  with  long-term  follow-up
42,43.  Ropinirole  may  have 
similar benefits in depression based on results from an open-label 
study
44. 
Targeting Excitatory Amino Acids 
The  NMDA  receptor  is  an  ionotropic  glutamate  receptor  with 
highest  densities  located  in  cortico-limbic  regions  of  the  brain. 
Extracellular  glutamate  concentrations  are  enhanced  by  various 
stressors, like  tail  pinch and restraint,  and  an involvement  of  the 
NMDA  receptor  became  apparent  in  the  modulation  of  stress-
induced  glutamate  responses
45,  46.  Furthermore,  chronic 
antidepressant  administration  can  influence  NMDA  receptor 
function and receptor binding profiles, as well as generate regional 
alterations  in  mRNA  expression  that  encodes  multiple  NMDA 
receptor  subunits
47,48.  An  extensive  library  of  noncompetitive 
NMDA  antagonists  (e.g.,  MK-801,  memantine,  ketamine)  that 
reduce  glutamatergic  transmission  at  the  NMDA  receptor  have 
demonstrated antidepressant-like effects in animal models, including 
forced swim and tail suspension tests, inescapable stressors, and in 
learned helplessness
49,50. 
With this in mind, the direction of major research efforts for the 
treatment  of  depression  and  affective  disorders now  encompasses 
the  development  of  compounds  that  regulate  the  target-rich 
environment within the NMDA receptor complex. 
Targeting GABA 
GABA  is  the  primary  inhibitory  neurotransmitter  in  the  CNS. 
GABA  has  been  implicated  in  a number  of  psychiatric  disorders 
including schizophrenia and affective disorders. A number of studies 
have been carried out to assess the concentration of GABA in CSF 
or plasma in patients suffering from psychiatric disorders. The most 
consistent results are from studies in depressed patients. 
A number of research groups have reported CSF levels of GABA to 
be  significantly  decreased  in  depressed  patients
51-53.  Furthermore, 
studies of plasma levels of GABA in depressed patients concur with 
these  findings
54.  Using  proton  magnetic  resonance  spectroscopy, 
Sanacora  and  colleagues  have  measured  cortical  GABA 
concentrations  in  vivo.  Occipital  cortex  GABA  concentrations  in 
depressed  patients  were  found  to  be  significantly  lower  than  in 
healthy controls
55. Subsequent studies demonstrated that these low 
levels  of  GABA  were  normalized  after  SSRI  treatment. 
Interestingly, low levels of GABA in plasma of depressed patients 
were  not  reversed  by  desipramine  treatment
56.  The  decreases  in 
GABA observed in depressed patients do not appear to be associated 
with  changes  in  GABA  uptake  binding  sites.  Neither  GABA  B 
receptors  nor  glutamic  acid  decarboxylase  (GAD;  biosynthetic 
enzyme  for  GABA)  activity  have  been  found  to  be  altered  in 
depressed  suicide  victims,  whereas  GABA  A  receptor  binding in 
frontal cortex was increased in depressed suicide victims
57,58. The 
putative  role  of  GABA,  GABA  A,  and  GABA  B  receptors  in 
depression  could  be  mediated  directly  by  GABA  or  via  other 
neurotransmitter  systems.  There  are  pieces  of  evidence  linking 
GABA B receptors to noradrenergic and serotonergic systems. For 
example, administration of GABA B receptor antagonists has also 
been demonstrated to cause downregulation of beta adrenoceptors, 
an effect common to chronic administration of a number of types of 
antidepressants
59,60. The GABA B antagonist, phaclofen, as well as 
the  GABA  A  receptor  antagonist,  bicuculline,  increased 
norepinephrine  release  in  the  median  preoptic  nucleus  in  vivo. 
Conversely,  locally  applied  agonists  of  GABA  A  and  GABA  B 
receptors (muscimol and baclofen, respectively) decreased dialysate 
levels of norepinephrine in the same area. These data indicate that 
GABA  A  and  GABA  B  receptors  are  involved  in  the  control  of 
norepinephrine release in this part of the rat brain
61. Local infusion 
of the GABA A receptor antagonist, bicuculline, increases serotonin 
release in the dorsal raphe, indicating that GABA afferents exert a 
tonic  inhibitory  influence  on  serotonin  neurones  in  the  dorsal 
raphe
62.  In  terms  of  behavioral  effects  of  GABAergic  drugs,  the 
profile of the GABA B antagonist, CGP56433 in the forced swim 
test  indicates  a  serotoninmediated  effect;  CGP56433  decreases 
immobility  and  increases  swimming,  a  profile  comparable  with 
fluoxetine
63.
 
Thus, GABA is strongly implicated in depression such that GABA 
receptors  are  potential  targets  for  the  development  of  novel 
antidepressants 
Novel Pharmacological Targets: Beyond Monoamines 
In the area of depression research, interest in central peptide systems 
has  focused  on  the  high-profile  efforts  targeting  receptors  of  the 
central substance P [neurokinin 1 (NK1)] and corticotropin-releasing 
factor (CRF1) systems. This has led to the development of numerous 
compounds now in clinical trials for depression. In addition to NK1 
and CRF1, however, interest has also fallen on receptors involved in 
mediating  the  effects  of  other  central  peptidergic  systems.  These 
include  examples  such  as  melanin-concentrating hormone  (MCH) 
and arginine vasopressin. 
Corticotropin-releasing factor (CRF)-1 receptor antagonists 
Increased activity of the hypothalamic–pituitary–adrenal (HPA) axis 
is a major component of the mammalian endocrine stress response. 
Following a stressful encounter, the neuropeptide CRF is secreted 
into the hypothalamohypophysial portal circulation where it acts to 
stimulate  the  release  of  adrenocorticotropin  (ACTH)  from  the 
anterior pituitary. ACTH stimulates glucocorticoid production and 
release from the adrenal cortex. Stress (physical or emotional) can 
precipitate  or  worsen  depression  in  vulnerable  individuals.  A 
burgeoning database links HPA axis activity and more specifically 
CRF to this process. Compared to nondepressed controls, depressed 
or depressed suicidal patients show increased HPA axis activity and 
elevated  cerebrospinal  fluid  (CSF)  CRF  concentrations,  increased 
paraventricular nucleus (PVN) CRF mRNA expression, and a larger 
number  of  CRF-expressing  neurons  in  the  PVN
64.  In  healthy 
volunteers, desipramine reduces CSFCRF  concentrations
65, and in 
depressed patients fluoxetine and ECT have shown similar effects
66. 
These  data  suggest  that  antidepressant  treatments  with  different 
mechanisms of action may ultimately reduce CRF activity as part of 
their  mechanism  of  action.  Consequently,  research  is  focusing 
closely on the antidepressant potential of direct modulation of CRF 
neurotransmission. 
Two  main  CRF  receptor  subtypes,  CRF1  and  CRF2,  exist  in the 
central  nervous  system  (CNS).  CRF  binds  more  avidly  to  CRF1 
receptors  than  to  CRF2  receptors;  urocortin  is  the  preferred 
endogenous  ligand  for  CRF2  receptors.  Heightened  anxiety-like 
behaviors in animals have been connected to the decreased activity 
of  CRF2  receptors.  Several  CRF1  receptor  antagonists  possess 
anxiolytic-like  and  antidepressant-like  effects  in  animal  models
67. 
R121919 showed encouraging antidepressant effects in humans but 
its  development  was  discontinued  as  a  result  of  potential  liver 
toxicity
68. CP-316 311, another CRF1 receptor antagonist, did not 
show significant antidepressant effects in a placebo-controlled and 
sertraline-controlled trial 
69; however, it is unclear whether the dose 
tested was sufficient to block CNS CRF1 receptors effectively. NBI- Mehta Hiren R et al. IRJP 2011, 2 (12), 132-138 
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34041, a third agent, has not yet been tested in depressed patients 
but  in  healthy  humans  has  shown  an  ability  to  attenuate  the 
endocrine stress response
70.  
Inhibition of Glucocorticoid Function 
Decreased synthesis or receptor blockade of adrenal glucocorticoids 
may  have  antidepressant  effects.  Ketaconozale,  aminogluthemide, 
and metyrapone are agents that interfere with cortisol synthesis. All 
of  these  have  shown  some  antidepressant  potential,  but  adverse 
events have limited their development
71. Mifepristone, also known 
as  RU486,  is  a  glucocorticoid  2  receptor  antagonist  that  showed 
antidepressant  efficacy  in  an  early  case  series  of  patients  with 
severe, chronic depression
72. Two additional studies in patients with 
severe,  psychotic  depression  (one  open-label  and  one  placebo-
controlled) both found mifepristone to be safe and efficacious, with 
therapeutic effects seen within one week
73,74. Because these benefits 
were  primarily  in  psychotic  symptoms  and  not  in  depressive 
symptoms, this agent may be more appropriate for treating psychotic 
depression. 
Substance P (Nk-1) Antagonists 
Neurokinins  are neuropeptides  involved  in nociception  and  many 
other  physiologic  processes.  Neurokinin  receptors  are  extensively 
distributed  in  the  CNS,  and  the  most  widely  distributed  receptor 
subtype  is  NK-1.  Substance  P  binds  to  NK-1  receptors  that  are 
located  in  high  density  in  the  hypothalamus,  periaqueductal  gray 
matter,  amygdala,  locus  ceruleus,  and  parabrachial  nucleus
75. 
Substance P-containing neurons contain 5HT and share projection 
targets  with  NE neurons
76,77.  A  behavioral  and  physiologic  stress 
response in animals has been associated with increases in substance 
P
78,79  and  attenuated  by  the  administration  of  an  NK-1 
antagonist
80,81. After exposure to a stressful stimulus, patients with 
MDD or PTSD exhibit elevated CSF substance P concentrations
82; 
decreased serum levels have been associated with an antidepressant 
response
83.  Preclinical  studies  show  that  various  NK-1  receptor 
antagonists possess antidepressant-like effects and several have been 
tested  in  humans.  Aprepitant  (MK-869)  showed  antidepressant 
efficacy  in  an  initial  placebo-controlled  trial
84,  but  subsequent 
controlled studies failed to confirm this finding
80. L-759274 and CP-
122721  demonstrated  antidepressant  effects  in  pilot  studies
85,86, 
though replication has not been reported for either. GR-205171 has 
shown  preliminary  efficacy  in  social  phobia
87  and  antidepressant-
like effects in an animal model
88. 
MCH1 Receptor Antagonists 
Melanin  concentrating  hormone  is  a  lateral  hypothalamic 
neuropeptide with a well-established role in the regulation of food 
intake and energy balance
89. More recently, blockade of this target 
has been linked to antidepressant and anxiolytic properties in animal 
models
90, through enhancement of glutamaergic transmission in the 
shell of the nucleus accumbens (NuAcc)
91. The NuAcc is central to 
the modulation of goal directed behaviors for natural rewards
92–94. 
MCH  seems  to  play  an  important  role  in  the  modulation  of 
hypothalamic–NuAcc interactions, and therefore MCH1 antagonists 
may  be  able  to  modulate  hedonic  drive
95–  97.  In  fact,  making  a 
parallel  with  paradoxical  effects  of  CRF  in  the  NuAcc  on  cue-
triggered motivation for sucrose intake
98, one could speculate that 
MCH1 antagonists may actually stimulate palatable food intake as 
part  of  an  enhancement  of  hedonic  drive.  In  addition,  MCH1 
antagonists induce hippocampal neurogenesis after 4 weeks chronic 
treatment  in  the  mouse,  a  process  that  has  been  associated  with 
chronic antidepressant and chronic anxiolytic activity
99. Finally, the 
MCH  system is one  of the many peptidergic pathways known to 
modulate  the  HPA  axis
100.  Anhedonia,  with  loss  of  taste  and 
appetite, and HPA axis overactivity are key features of melancholic 
depression. It is hypothesized that such patients may be a relevant 
target population for MCH1 antagonists. As this is a relatively new 
area,  several  outstanding  questions  remain:  How  does  the  MCH 
system interact with classical neurotransmitters in relevant disease 
state models? What is the impact of MCH2, a second MCH receptor 
in humans
101 (rodents have  only  one)? Is there any  evidence that 
MCH1  plays  a  critical  role  in  non-human  primates?  Even  in  the 
absence of answers to these questions, many companies are working 
on this target with at least one in phase I trials (for obesity as the 
primary indication). Progress toward the clinic has been slowed by 
difficulty  in  optimization  of  compounds  with  adequate 
cardiovascular safety as well as other ‘drugability’ issues
102. 
Gal3 Receptor Antagonists 
The neuropeptide galanin is widely distributed in the mammalian 
CNS  and  modulates  multiple  feeding,  cognitive  and  affective 
behaviors.  Pathological hyperactivity  in  the  LC results  in  galanin 
release inhibiting dopaminergic pathways to the forebrain, resulting 
in reduced locomotor activity and anhedonia
103. However, the co-
storage and co-release of galanin and norepinephrine described in 
rodents  CNS,  is  not  seen  in  human  LC
104,  and  the  anatomical 
distribution  of  galanin  in  the  brain  differs  significantly  between 
rodents  and  higher  primates
105.  Galanin  is  also  known  to  be  an 
inhibitory modulator of both acetylcholine and serotonin release in 
the rat hippocampus
106, arguing in favor of the potential usefulness 
of galanin antagonists for the treatment of depression. In rats, ECT 
increases  galanin  mRNA  in  the  dorsal  raphe  nucleus  and  sleep 
deprivation augments galanin mRNA in the locus coeruleus
107 and in 
depressed patients, intravenous administration of galanin is followed 
by rapid and acute antidepressant like effects
108. 
Arginine vasopressin 
Arginine  vasopressin  (AVP)  is  a  cyclic  nonapeptide  synthesized 
exclusively by neurosecretory cells of the CNS with a diverse array 
of biological functions based on differences in sites of release. AVP 
released into the portal circulation from the median eminence is also 
known to directly modulate CRF effects on ACTH release and the 
HPA axis. The central vasopressinergic system has been examined 
as  a  platform  for  psychiatric  drug  development,  including 
depression
109. The central vasopressinergic system acts on several 
key  neural  substrates  underlying  aspects  of  the  depression 
endophenotype,  including  monaminergic  systems  and  those 
regulating memory,  pain  sensitivity,  synchronization  of  biological 
rhythms, the timing/quality of R.E.M. sleep, and regulation of fluid 
and  electrolyte  homeostasis
110.  Disturbances  (hyperactivity)  in 
vasopressinergic  activity  have  also  been  reported  clinically  in 
patients  with  depression
111,112.  Together,  this  has  led  many  to 
hypothesize  the  utility  of  central  vasopressinergic  receptor 
antagonism as a potentially novel antidepressant strategy. 
CONCLUSION 
Despite  the  efficacy  of  our  currently  available  antidepressant 
medications  and  somatic  therapies,  residual  depressive  symptoms 
and relapse are common. This creates a challenge for the clinician as 
s/he seeks to completely eliminate symptoms and help patients fully 
recover.  To  reach  these  goals,  improved  treatment  strategies  are 
needed. Understanding the neurobiology  of depression has helped 
researchers  uncover  a  number  of  novel  targets  for  antidepressant 
therapies.  Over  the  next  decade,  proof-of-concept  studies  will  be 
performed in the clinic for a wide array of mechanisms and the true 
validity of these novel strategies will be enlightening. This will not 
only  include  combination  molecules  taking  further  advantage  of 
monoaminergic approaches but novel mechanisms yet to be tested in 
humans. Clearly, the current array of animal models for determining 
antidepressant  activity  has  been  useful  in  predicting  therapeutic 
efficacy  of  multiple  monoaminergic  mechanisms.  Notably, 
mechanisms  that  do  not  directly  or  indirectly  modulate 
monoaminergic  mechanisms  remain to  be  fully  validated  and  the 
development  of  further  animal  models  may  be  necessary.  In 
conclusion, the most successful novel approaches will be those that 
not  only  demonstrate  preclinical  antidepressant-  like  effects,  but Mehta Hiren R et al. IRJP 2011, 2 (12), 132-138 
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those  that  target  the  unmet  clinical  needs  and  lead  to  long-term 
disease modification. For many of the approaches described in this 
review,  clinical  testing  will  determine  the  extent  to  which  these 
approaches  show  distinct  advantages  over  existing  therapies  and 
finally demonstrate the true innovation associated with these novel 
mechanisms. 
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